The U.S. Food and Drug Administration granted Fast Track Designation for CNS Pharmaceuticals Inc.'s (CNSP) lead investigational drug, Berubicin, for the treatment of patients with recurrent glioblastoma multiforme or GBM.
The Fast Track Designation enables more frequent interactions with the FDA to expedite the development and review process for drugs intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical need.
CNS recently announced the start of patient enrollment in its potentially pivotal study of Berubicin for the treatment of recurrent glioblastoma multiforme.
The company had also received Orphan Drug Designation from the FDA for Berubicin for the treatment of patients with recurrent GBM.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.